Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 3/20 | 0.55 |
| ▸ | GRM5 | P41594 | 4/20 | 0.40 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | VNN1 | O95497 | 4/20 | 0.38 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.38 |
| ▸ | CCR2 | P41597 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21726649 | 0.83 | GSK3B (0.50) | GSK3BKDM2B | |
| SCHEMBL29581628 | 0.82 | GSK3B (0.59) | GSK3BGRM5VNN1KMT2A | |
| SCHEMBL17064976 | 0.82 | GSK3B (0.59) | GSK3BGRM5VNN1KMT2A | |
| SCHEMBL8105775 | 0.81 | GSK3B (0.74) | GSK3BGRM5VNN1GPR139KMT2A | |
| SCHEMBL19707270 | 0.79 | ALDH1A1 (0.46) | KMT2A | |
| SCHEMBL13571053 | 0.78 | GSK3B (0.66) | GSK3BGRM5VNN1GPR139 | |
| SCHEMBL18630550 | 0.78 | L3MBTL1 (0.50) | KMT2A | |
| SCHEMBL19707531 | 0.76 | GSK3B (0.62) | GSK3BGRM5GPR139 | |
| SCHEMBL31542041 | 0.75 | GSK3B (0.66) | GSK3BVNN1GPR139KMT2A | |
| SCHEMBL29556203 | 0.75 | GSK3B (0.70) | GSK3BGRM5VNN1GPR139 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017214505-A1 | CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2017-12-14 | — | — | WO | disclosed |